<DOC>
	<DOCNO>NCT02529202</DOCNO>
	<brief_summary>The goal proposal profile pharmacokinetics dexmedetomidine newborn â‰¥36 week post-menstrual age therapeutic hypothermia hypoxic-ischemic encephalopathy .</brief_summary>
	<brief_title>Dexmedetomidine Pharmacokinetics Neonates During Therapeutic Hypothermia</brief_title>
	<detailed_description>The goal proposal determine pharmacokinetics ( PK ) dexmedetomidine ( DEX ) newborns neonatal intensive care unit ( NICU ) receive therapeutic hypothermia ( TH ) moderate severe hypoxic-ischemic encephalopathy ( HIE ) . In newborns HIE , TH 72 hour standard therapy mitigate brain damage . Most HIE patient receive mechanical ventilation TH thus sedate morphine . Unfortunately , morphine negative side effect specifically prevent shiver . Prevention shiver critical success TH , shiver negates cool . DEX particularly promise alternative sedative prevent shiver already use NICUs sedation pain management . In newborn , DEX PK data set TH available need determine properly dose DEX HIE patient .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Hypothermia</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Hypoxia-Ischemia , Brain</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Adrenergic alpha-2 Receptor Agonists</mesh_term>
	<mesh_term>Central Nervous System Depressants</mesh_term>
	<criteria>1 . Newborns 36 week gestation old moderate severe hypoxicischemic encephalopathy identify treat therapeutic hypothermia Seattle Children 's Hospital neonatal intensive care unit . 2 . Cooled infant initially intubate mechanically ventilate . 3 . Infants anticipate require 72 hr continuous sedation and/or treatment prevent shiver . 4 . Subject 's parent ( ) legal guardian ( ) has/have voluntarily sign date informed consent document approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) . 1 . Known chromosomal anomaly . 2 . Newborns without central line ( e.g. , line need unable successfully place ) without peripheral arterial line . 3 . Patients know cyanotic congenital heart defect 4 . Patients participate another clinical trial . 5 . Patients receive DEX prior enrollment study 6 . At discretion Investigator , subject risk Dexmedetomidine treatment expect exceed benefit .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Day</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Dexmedetomidine</keyword>
	<keyword>Neonate</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Therapeutic Hypothermia</keyword>
	<keyword>Hypoxic-ischemic Encephalopathy</keyword>
	<keyword>Adrenergic Agents</keyword>
	<keyword>Adrenergic Agonists</keyword>
	<keyword>Analgesics</keyword>
	<keyword>Adrenergic alpha-2 Receptor Agonists</keyword>
	<keyword>Central Nervous System Agents</keyword>
	<keyword>Central Nervous System Depressants</keyword>
</DOC>